NCT06722157

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Randomized, Double-masked, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of Two Regimens of Intravitreal BI 771716 Against Pegcetacoplan in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration VERDANT Trial

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 202 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy. In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye. Participants are in the study for a little longer than a year and visit the study site every 4 weeks. At the visits, the study doctor checks the eyes of the participants. The results are compared between the groups of participants to see whether the treatment works. The study doctor also regularly checks participants' health and takes note of any unwanted effects.

Conditions

• Macular Degeneration, Age-related
• Geographic Atrophy

Interventions

Type	Name	Description
DRUG	BI 771716	BI 771716
DRUG	Pegcetacoplan	Pegcetacoplan
DRUG	Sham comparator to BI 771716	Sham comparator to BI 771716

Timeline

• Start date: 2025-01-06
• Primary completion: 2026-10-16
• Completion: 2026-10-16
• First posted: 2024-12-09
• Last updated: 2026-01-29

Locations

46 sites across 1 country: United States

Regulatory

• FDA-regulated drug study